Salute e Benessere

Midea Group Releases Sustainable Heating Solutions for Europe at ISH 2025

As a global tech-leading company, Midea will be showcasing new products at ISH 2025 that will be instrumental in further reducing energy consumption through a suite of innovative features led by its R290 heating solutions. By applying R290 on a great scale, Midea was able to reduce emissions by 3.715 mil tons of CO2 from its 6.2 mil sets sold to date worldwide. As a global tech-leading company, Midea will be showcasing new products at ISH 2025 that will be instrumental in further reducing...
PR Newswire
17/03/2025

Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites

Curia's sterile fill-finish facility in Glasgow will add an integrated, isolator-based vial filling line and lyophilizer suitable for a broad range of drug product including highly potent capabilities, more than doubling current GMP batch size. Already known for its antibody drug conjugates (ADCs), lipid nanoparticles (LNPs), lyophilization development, complex formulation and development, and clinical manufacturing experience, the Glasgow expansion will further strengthen Curia's offering...
Nasdaq GlobeNewswire
17/03/2025

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being held March 16-18, 2025, in Dana Point, California. This year's event will...
Nasdaq GlobeNewswire
17/03/2025

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of…

"This IND submission underscores our commitment to advance transformative RNAi therapies for patients with severe lipid disorders," said Stella Shi, CEO and Founder of Rona Therapeutics. "RN0361's Phase I data validate its potential as a best-in-class siRNA with durable efficacy and patient-friendly dosing. We look forward to collaborating with global investigators and agency to accelerate its development." "This IND submission underscores our commitment to advance…
PR Newswire
17/03/2025

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_12_Share_buyback_program
Nasdaq GlobeNewswire
17/03/2025

iOnctura strengthens leadership with appointments of Chief Business Officer and…

Prior to her career in biopharmaceuticals, she was an Associate Partner with McKinsey & Company where she advised senior management in life sciences and healthcare on a range of strategy, organization and M&A projects. She holds an MBA from NYU Stern School of Business and an MSc from the London School of Economics. Prior to her career in biopharmaceuticals, she was an Associate Partner with McKinsey & Company where she advised senior management in life sciences and healthcare on a…
PR Newswire
17/03/2025

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company…

March 17 th, 2025 Taiho Pharmaceutical Co., Ltd. Araris Biotech AG Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced today that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully...
Nasdaq GlobeNewswire
17/03/2025

POLYTECH Health & Aesthetics Launches New UK Subsidiary

With this expansion, surgeons and patients across the UK will now have direct access to POLYTECH's differentiated product portfolio, including B-Lite®, the world's only lightweight breast implants, as well as the highly regarded MESMO® and Microthane® implants—recognised globally for their innovation, safety, and quality. With this expansion, surgeons and patients across the UK will now have direct access to POLYTECH's differentiated product portfolio, including B-Lite®, the world's only...
PR Newswire
17/03/2025

Healthcare Holding Schweiz Acquires Effectum CH-Rep (Switzerland)

Fabio Fagagnini, CEO of Healthcare Holding Schweiz, expressed his enthusiasm for the acquisition: "With Effectum CH-Rep, we are expanding our service portfolio to include the role of Swiss Authorized Representative, thereby strengthening our growing group. This allows our sales representatives and managing directors to focus even more on innovative products and exceptional customer service, with the assurance that all regulatory requirements are being professionally met." Fabio…
PR Newswire
17/03/2025

Prioritizing Sleep Health: BMC Medical Advocates Better Sleep at 3S Congress

And on March 15th, BMC Medical participated in the 3S Congress in France, hosting a workshop focused on advancing sleep therapy solutions. Dr. Julien Favier and Mr. Ludovic Abuaf shared insights on industry trends and BMC's innovations, highlighting how smart CPAP technology and digital health solutions are transforming sleep care. The G3 A20 CPAP and PAP Link Digital Health Solution were featured as key advancements in personalized and accessible sleep apnea management. And onMarch 15th,...
PR Newswire
17/03/2025

4baseCare Secures CAP Accreditation, Elevating Genomic Profiling Standards for…

"Our mission is to democratize access to high-quality genomic insights, empowering oncologists with cutting-edge molecular data to drive better patient outcomes," said Dr. Sudharshan Elangovan, VP of Global Operations, 4baseCare. "Our mission is to democratize access to high-quality genomic insights, empowering oncologists with cutting-edge molecular data to drive better patient outcomes," saidDr.Sudharshan Elangovan, VP of Global Operations, 4baseCare. Syed Hussaini…
PR Newswire
17/03/2025

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the…

Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMSAllschwil, Switzerland – March 17, 2025Idorsia Ltd (SIX: IDIA) today announced that – effective immediately – the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO is Idorsia's dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in...
Nasdaq GlobeNewswire
17/03/2025

Roche to share latest scientific advancements from its neuromuscular portfolio…

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA)Late-breaking oral on Elevidys' Embark two-year data and pooled analysis of Study 101, 102 and Endeavor, demonstrated clinically meaningful and statistically significant improvements across key measures of motor function in boys with Duchenne muscular dystrophy (DMD)Muscle pathology as measured by MRI...
Nasdaq GlobeNewswire
17/03/2025

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO…

SKY-0515 is Skyhawk's investigational small molecule RNA splicing modifier developed through the company's novel RNA-splicing platform. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 is Skyhawk's investigational small molecule RNA splicing modifier developed through the company's novel RNA-splicing platform. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional key...
PR Newswire
15/03/2025

The British Beauty Council's Sustainable Beauty Coalition is launching 'The…

In addition, in 2023 research found that although 79.3% of consumers view sustainability as important when making purchasing decisions, only 23.4% currently use refillable skin care products[2]. In addition, in 2023 research found that although 79.3% of consumers view sustainability as important when making purchasing decisions, only 23.4% currently use refillable skin care products[2] . With support from leading high-street retailers including Boots,John Lewis, Tesco and more, the...
PR Newswire
14/03/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments Notification of managers' transaction - Riad Sherif - Mar 2025 RSUNotification of managers' transaction - Sylvia Cheung - Mar 2025 optionNotification of managers' transaction - Pall Ragnar Johannesson - Mar 2025 optionNotification of managers' transaction - Lionel Carnot - March 2025 purchase
Nasdaq GlobeNewswire
14/03/2025

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the…

Total position of W&M GmbH according to the notification: Notified details of the resulting situation on the date on which the threshold was crossed: After14 March 2025, W&M GmbH holds 5.78% of the shares and votes. Further enquiries Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating...
PR Newswire
14/03/2025

Bioretec Ltd's Annual Report 2024 published

Further enquiries Further enquiries Alan Donze, CEO, +1 619 977 5285Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture...
PR Newswire
14/03/2025

Notice to Convene Annual General Meeting 2025 - Item 6: Election of members to…

Company announcement no. 4– 25 14 March 2025 Notice to Convene Annual General Meeting 2025 - Item 6: Election of members to the Board of Directors Following the publication of the Notice to Convene the Annual General Meeting 2025 of NTG Nordic Transport Group A/S (Company announcement no. 3 – 25), the Company is pleased to announce that upon recommendation from the Nomination Committee, the Board of Directors proposes to elect Lene Borne as a new independent member of the Board of...
Nasdaq GlobeNewswire
14/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 14 MARCH 2025 at 15.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly or through financial instruments by BlackRock, Inc. and its funds increased on 13...
Nasdaq GlobeNewswire
14/03/2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital...
Nasdaq GlobeNewswire
14/03/2025

Azurity Pharmaceuticals Completes Acquisition of Covis Pharma

Strategic Benefits of the Acquisition: Strategic Benefits of the Acquisition: "We are excited to welcome Covis Pharma to Azurity," said Ronald Scarboro, CEO of Azurity. "The efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by…
PR Newswire
14/03/2025

Coloplast Finance B.V. - Decisions at the Annual General Meeting

On 14 March 2025, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24. In addition, Ernst & Young Accountants LLP was appointed as auditor for Coloplast Finance B.V. Attachment 02-2025-decisions-at-the-annual-general-meeting-coloplast-finance-bv
Nasdaq GlobeNewswire
14/03/2025

Avextra Showcases Study Findings on World Sleep Day 2025

Cannabis-Based Therapy Shows Promise in Improving Sleep Quality and Pain Management Bensheim, Germany– 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association. The impact of insufficient sleep on not only individuals but the health system and the economy can hardly be underestimated. Recent data has uncovered a correlation between chronic sleep...
Nasdaq GlobeNewswire
14/03/2025
Altri  Comunicati